Reaction: Erdafitinib to 1 product
- Reaction
- Reaction type
- O-demethylation
- Direction
- Major circulating metabolite?
- No
- Spontaneous?
- No
- Activity
- unknown
- References
- Scheers E, Borgmans C, Keung C, Bohets H, Wynant I, Poggesi I, Cuyckens F, Leclercq L, Mamidi RNVS: Metabolism and disposition in rats, dogs, and humans of erdafitinib, an orally administered potent pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor. Xenobiotica. 2021 Feb;51(2):177-193. doi: 10.1080/00498254.2020.1821123. Epub 2020 Sep 20. [Article]
- FDA Approved Drug Products: BALVERSA® (erdafitinib) tablets, for oral use [Link]
- Health Canada Approved Drug Proucts: BALVERSA (Erdafitinib) tablets, for oral use [Link]
- Comments
- Not Available
- Enzymes
Enzyme Km Vmax Role Cytochrome P450 2C9 Not Available Not Available implied Cytochrome P450 3A4 Not Available Not Available implied
